Activities of Karin KADENBACH related to 2012/2041(INI)
Shadow reports (1)
REPORT on the Microbial Challenge – Rising threats from Antimicrobial Resistance PDF (224 KB) DOC (156 KB)
Amendments (38)
Amendment 9 #
Motion for a resolution
Recital D
Recital D
D. whereas the rise of antimicrobial resistance (AMR) is a complex issue driven by a variety of interconnected factors; whereas individual intervention measures will have minimal effect;
Amendment 15 #
Motion for a resolution
Recital F
Recital F
F. whereas, given the lack of new antibacterial drug development, it is of paramount importance that the effective exploitation of existing antimicrobials is maintained for as long as possible via prudent use, infection spread prevention, vaccinations, alternative treatments, prudent use and controlled antimicrobial dosage;
Amendment 25 #
Motion for a resolution
Recital H a (new)
Recital H a (new)
Ha. whereas bacterial resistance ignores national borders and the problem cannot be solved overnight; whereas it is of uttermost importance to elaborate on a strong collaboration between countries and sectors;
Amendment 29 #
Motion for a resolution
Recital H b (new)
Recital H b (new)
Hb. whereas the use of diagnostics have a vital role to play in combating AMR by encouraging more targeted approaches to treatment;
Amendment 31 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Considers that, while almost all Member States have developed national AMR strategies in accordance with the Council Recommendation on prudent use of antimicrobial agents in human medicine, progress with regard to meeting set objectives has been slow and uneven; calls for firm governmental commitment to full and timely implementation at national level;
Amendment 32 #
Motion for a resolution
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Welcomes the Commission's five-year strategic Action Plan on tackling AMR, but expresses concern that many of the action points reiterate measures prescribed over a decade earlier in the Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine;
Amendment 34 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Underlines that the key objective of any AMR strategy is to maintain the efficiency of existing antimicrobials by using them responsibly at the correct therapeutic level only when strictly necessary and prescribed over a limited time at the appropriate dosage, and reducing the use of antimicrobials in general and especially of Critically- Important Antimicrobials (CIAs)14 in human and veterinary medicine; underlines the absolute need for an active holistic approach based on a 'One Health' perspective with the purpose of a better and more efficient coordination between the human health sector and the veterinary sector;
Amendment 35 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Underlines that the key objective of any AMR strategy is to maintain the efficiency of existing antimicrobials by using them responsibly at the correct therapeutic level only when strictly prescribed over a limitedspecific time at the appropriate dosage, and reducing the use of antimicrobials in general and especially of Critically- Important Antimicrobials (CIAs)14 in human and veterinary medicine thereby also taking into account the OIE List of Antimicrobial Agents of Veterinary Importance (OIE List);
Amendment 37 #
Motion for a resolution
Paragraph 2 – footnote 14
Paragraph 2 – footnote 14
14. Report of the first3rd meeting of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR), Copenhagen, 2009, 14-17 June 2011, Oslo, Norway.
Amendment 45 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Stresses that more efforts are needed to control the use of antimicrobials in the human and veterinary sectormedicine; strongly disapproves of the uncontrolled prophylactic use of antimicrobials in animal husbandry;
Amendment 53 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Calls on the Commission to come up with a legislative proposal for the veterinary sector to limit the use of third- and fourth-generation CIAs for humans; stresses that any such proposal must be founded on evidence-based European guidelines on the prudent use of antimicrobials in veterinary medicine;
Amendment 55 #
Motion for a resolution
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Calls on the Commission to give serious consideration to reviewing Directive 2001/82/EC, including altering the definition of the prescription of antimicrobial veterinary medical products so that antibiotics can only be prescribed by professionally qualified veterinarians;
Amendment 56 #
Motion for a resolution
Paragraph 5
Paragraph 5
5. Calls on the Commission to maintain its renewed momentumfollow up on its AMR Action Plan with concrete initiatives to implement the 12 actions and publish its progress report on implementation of the AMR Action Plan by the end of 2013;
Amendment 58 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. CStresses that there are substantial differences amongst Member States in how antibiotics are used and distributed; calls on the Commission to assess and monitor Member States' implementation of the relevant European legislation on antimicrobials, especially with regard to the prescription-only use of antibiotics and the ban on antimicrobials as growth promoters in animal feed;
Amendment 60 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Calls on the Commission to examine the condition for prescription and sale of antimicrobials in order to ascertain whether practices in human and animal healthcare may lead to over-prescription, overuse or misuse of antimicrobials;
Amendment 62 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Calls on the Commission to monitor the use of nanosilver in consumer products as it might cause an increasing resistance of micro-organisms against silver, including nanosilver and silver based compounds, which may limit the usefulness of nanosilver in medical devices and other medical applications;
Amendment 64 #
Motion for a resolution
Paragraph 6 b (new)
Paragraph 6 b (new)
6b. Calls on the Commission to consider legislation which separates veterinarians' right to both prescribe and sell antimicrobials. thereby eradicating economic incentives to prescribe;
Amendment 66 #
Motion for a resolution
Paragraph 6 c (new)
Paragraph 6 c (new)
6c. Calls on the Commission to examine the feasibility of drawing up European clinical guidelines for treatment of specific diseases with antimicrobials based on fundamental principles, such as only allowing a doctor to prescribe antimicrobials if he or she has seen the patient and a diagnosis has been given, and choosing narrow-spectrum antimicrobials wherever possible;
Amendment 69 #
Motion for a resolution
Paragraph 7
Paragraph 7
7. With a view to limiting the use and easy availability ofinappropriate use and uncontrolled access to antimicrobial agents, welcomes Member States' initiatives to review the legal status of all oral, inhaled and parenteral antibiotics (namelymicrobials (including antimalarial, antiviral and antifungal drugs) that remain available to patients without a prescription;
Amendment 70 #
Motion for a resolution
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Emphasises the need to combat the increasing problem of illegal internet sales of antimicrobials;
Amendment 76 #
Motion for a resolution
Paragraph 9
Paragraph 9
9. Calls on the Commission and Member States, in accordance with the competent EU Agencies, to devise and promote prudent use guidelines aimed at reducing non-essential and inappropriate exposure to antimicrobials in human and veterinary medicine, livestock farming, agriculture, aquaculture and horticulture;
Amendment 77 #
Motion for a resolution
Paragraph 9 a (new)
Paragraph 9 a (new)
9a. Welcomes moves by public authorities in the Member States to use vaccination as a key intervention in their AMR strategies but believes this should not replace good farm management and animal husbandry systems;
Amendment 83 #
Motion for a resolution
Paragraph 9 b (new)
Paragraph 9 b (new)
9b. Underlines that infection prevention and control is a vital cornerstone in the fight against AMR in human medicine; believes that research into the epidemiology of healthcare-associated infections (HAIs) due to MRSA and C. difficile and other emerging multidrug resistant organisms needs to be broadened out;
Amendment 85 #
Motion for a resolution
Paragraph 9 c (new)
Paragraph 9 c (new)
9c. Calls on the Commission and Member States to increase the exchange of best practice on preventing and reducing healthcare associated infections (HAIs);
Amendment 88 #
Motion for a resolution
Paragraph 10 a (new)
Paragraph 10 a (new)
10a. Calls on the Commission to invest in R&D aimed at alternatives for AMR use in livestock production and to support innovation in agriculture practices, in line with the goals of the future European Innovation Partnership on Agricultural Productivity and Sustainability;
Amendment 92 #
Motion for a resolution
Paragraph 12 a (new)
Paragraph 12 a (new)
12a. Notes the importance of access to rapid, reliable and affordable diagnostic tools in the development of new treatment strategies;
Amendment 93 #
Motion for a resolution
Paragraph 12 a (new)
Paragraph 12 a (new)
12a. Calls on the Member States to improve infection control in health care and raise standards of hygiene in hospitals and other health care facilities in order to avoid illnesses which would require the prescription of antibiotics;
Amendment 95 #
Motion for a resolution
Paragraph 12 b (new)
Paragraph 12 b (new)
12b. Calls on the Commission and Member States to strengthen incentives for public and private sector cooperation to reinvigorate antimicrobial research and development (R&D); believes that sharing knowledge and pooling resources through innovative public-private partnerships (PPPs) will be critical to ensuring the clinical efficacy and availability of existing antimicrobials;
Amendment 97 #
Motion for a resolution
Paragraph 12 d (new)
Paragraph 12 d (new)
12d. Calls on the Commission to ensure the development and availability of more on farm tools for early, rapid diagnosis and control of diseases, as well as a broad and effective diagnostic system at Member State level which can ensure the timely delivery of results in case bacteriological examinations are performed;
Amendment 101 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Stresses the importance of establishing an effective European network of national surveillance systems in the human health and veterinary sectors in order to facilitate the compilation of clear, comparable, transparent and timely reference data on antimicrobial drug usage; believes this should be based on the existing monitoring networks operated by EFSA, the ECDC European Surveillance of Antimicrobial Consumption Network (ESAC-nNet), the ECDC European Antimicrobial Resistance Surveillance Network (EARS-nNet), the ECDC Food- and Waterborne Disease Network (FWD-Net), and the EMA European Surveillance of Veterinary Antimicrobial Consumption (ESVAC);
Amendment 105 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14a. Calls on Member States to promote closer inter-sectoral collaboration between relevant authorities and sectors to encourage a more integrated veterinary-human health approach and monitor the implementation of national antimicrobial resistance strategies;
Amendment 106 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14a. Emphasises the need to support sustainable food production systems which in contrast to ''factory farming'' are potentially less exposed to AMR;
Amendment 108 #
Motion for a resolution
Paragraph 14 b (new)
Paragraph 14 b (new)
14b. Calls on the Commission and Member States to ensure that future measuring and reporting on the use of antimicrobials in both the human and veterinary sectors will be broadened out, showing not only the total amount of antimicrobials used but also types of antimicrobials, treatment times, etc.;
Amendment 111 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Notes that the encouragement of appropriate antimicrobial use depends on a change of attitudeinal and practice change among patients, farmers and, practitioners and pharmacists in the spheres of veterinary and human medicine; considers that more effective and continuous educational and training measures should be taken at both national and European level; , as well as comprehensive information in schools, generally from an early age, should be taken at both national and European levels to raise awareness of the inherent danger of antimicrobials;
Amendment 116 #
Motion for a resolution
Paragraph 16
Paragraph 16
16. Welcomes the annual European Antibiotic Awareness Day (18 November) instituted to promote the responsible use of antimicrobials; considers, however, that its visibility and potential could be more effectively maximised through strengthened political support at national and European levels, a broader approach which covers also animals, and coordinated, innovative and high-impact campaigns based on the experience derived from successful European and international initiatives;
Amendment 118 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Calls on the Commission to compile a best practice list with regard to the implementation of effective communication campaigns and professional training courses aimed at raising AMR awareness whereas information amongst citizens as well as health and veterinarian professionals is key to a better awareness and hence prevention;
Amendment 122 #
Motion for a resolution
Paragraph 19 a (new)
Paragraph 19 a (new)
19a. Calls on the Commission to build on the work of the TATFAR and promote similar multilateral and bilateral commitments for the prevention and control of AMR with other global partners;
Amendment 124 #
Motion for a resolution
Paragraph 20 a (new)
Paragraph 20 a (new)
20a. Urges Member States and the Commission to encourage and promote global risk management initiatives, such as the WHO list of CIAs for human medicine and the OIE List of Antimicrobials of Veterinary Importance;